SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
Merck and mantro GmbH have established EdiMembre, Massachusetts, U.S.A., a Deep Tech spin-out in the alternative protein industry
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Its lead product, Dasynoc, is awaiting FDA approval with a PDUFA date of October 7, 2025
The technology offers scalable continuous granulation at 200 kg/hour, with the potential to exceed 500 kg/hour for certain granules
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Subscribe To Our Newsletter & Stay Updated